| 3901 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3902 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
32 |
| 3903 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 3904 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3905 |
Apheresis |
Autologous |
Amyloidosis |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3906 |
Apheresis |
Allogeneic |
Anaplastic Large Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
56 |
| 3907 |
Apheresis |
Autologous |
Angioimmunoblastic T-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 3908 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
54 |
| 3909 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
7 |
| 3910 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
40 |
| 3911 |
Apheresis |
Allogeneic |
Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
14 |
| 3912 |
Apheresis |
Allogeneic |
B-Cell Acute Lymphoblastic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
36 |
| 3913 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
59 |
| 3914 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
33 |
| 3915 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3916 |
Apheresis |
Autologous |
B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
49 |
| 3917 |
Apheresis |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2021 |
Standard Therapy |
Poland |
28 |
| 3918 |
Apheresis |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2021 |
Standard Therapy |
Poland |
11 |
| 3919 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3920 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
60 |
| 3921 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 3922 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
52 |
| 3923 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
45 |
| 3924 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
37 |
| 3925 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3926 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 3927 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
74 |
| 3928 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
31 |
| 3929 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 3930 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
18 |
| 3931 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 3932 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
59 |
| 3933 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
67 |
| 3934 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3935 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
34 |
| 3936 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
70 |
| 3937 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
71 |
| 3938 |
Apheresis |
Allogeneic |
Chronic Neutrophilic Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
67 |
| 3939 |
Apheresis |
Allogeneic |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 3940 |
Apheresis |
Allogeneic |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
50 |
| 3941 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
68 |
| 3942 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3943 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3944 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3945 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma – Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 3946 |
Apheresis |
Allogeneic |
Farber Disease |
Hematology |
2021 |
Standard Therapy |
Poland |
9 |
| 3947 |
Apheresis |
Allogeneic |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
54 |
| 3948 |
Apheresis |
Autologous |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
55 |
| 3949 |
Apheresis |
Autologous |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
64 |
| 3950 |
Apheresis |
Autologous |
Follicular Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3951 |
Apheresis |
Autologous |
Germ Cell Tumor |
Hematology |
2021 |
Standard Therapy |
Germany |
28 |
| 3952 |
Apheresis |
Allogeneic |
Hemophagocytic Lymphohistiocytosis (Hlh) |
Hematology |
2021 |
Standard Therapy |
Poland |
23 |
| 3953 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
41 |
| 3954 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
40 |
| 3955 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
27 |
| 3956 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
19 |
| 3957 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
26 |
| 3958 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
32 |
| 3959 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
21 |
| 3960 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
37 |
| 3961 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
30 |
| 3962 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
47 |
| 3963 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
36 |
| 3964 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
30 |
| 3965 |
Apheresis |
Allogeneic |
Hurler Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
2 |
| 3966 |
Apheresis |
Allogeneic |
Immunodeficiency |
Hematology |
2021 |
Standard Therapy |
Poland |
12 |
| 3967 |
Apheresis |
Allogeneic |
Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 3968 |
Apheresis |
Allogeneic |
Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 3969 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 3970 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
57 |
| 3971 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 3972 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
57 |
| 3973 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
63 |
| 3974 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
56 |
| 3975 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3976 |
Apheresis |
Allogeneic |
Metachromatic Leukodystrophy |
Hematology |
2021 |
Standard Therapy |
Poland |
60 |
| 3977 |
Apheresis |
Autologous |
Morbus Hodgkin |
Hematology |
2021 |
Standard Therapy |
Germany |
36 |
| 3978 |
Apheresis |
Autologous |
Morbus Hodgkin |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3979 |
Apheresis |
Autologous |
Morbus Hodgkin |
Hematology |
2021 |
Standard Therapy |
Germany |
21 |
| 3980 |
Apheresis |
Allogeneic |
Mucopolysaccharidosis |
Hematology |
2021 |
Standard Therapy |
Poland |
2 |
| 3981 |
Apheresis |
Allogeneic |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Poland |
44 |
| 3982 |
Apheresis |
Allogeneic |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Poland |
60 |
| 3983 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
70 |
| 3984 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 3985 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
53 |
| 3986 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
51 |
| 3987 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
61 |
| 3988 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3989 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 3990 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
57 |
| 3991 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 3992 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3993 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 3994 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
50 |
| 3995 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
47 |
| 3996 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
43 |
| 3997 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 3998 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
56 |
| 3999 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 4000 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
51 |